CN102614267A - Chinese medicinal composition for treating diabetic nephropathy and preparation method thereof - Google Patents
Chinese medicinal composition for treating diabetic nephropathy and preparation method thereof Download PDFInfo
- Publication number
- CN102614267A CN102614267A CN2012101204469A CN201210120446A CN102614267A CN 102614267 A CN102614267 A CN 102614267A CN 2012101204469 A CN2012101204469 A CN 2012101204469A CN 201210120446 A CN201210120446 A CN 201210120446A CN 102614267 A CN102614267 A CN 102614267A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- extract
- medicine composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition for treating diabetic nephropathy and a preparation method thereof. The composition is prepared by extracting the following Chinese medicines in parts by weight: 150-400 parts of astragalus, 150-400 parts of kudzuvine root, 100-300 parts of glossy privet fruit, 100-130 parts of red-rooted salvia root, 100-300 parts of winged euonymus twig and 50-250 parts of coptis root. The composition has the effects of tonifying qi and yin, removing heat to promote salivation and promoting blood circulation to remove meridian obstruction, and is a Chinese medicinal compound researched in combination with the traditional Chinese medicine theory and the conventional pharmacological research result based on the pathogenesis of diabetic nephropathy. As proved by experimental research, the Chinese medicinal composition has a remarkable curative effect on diabetic nephropathy and high safety.
Description
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to a kind of Chinese medicine composition of treating diabetic nephropathy and preparation method thereof.
Background technology
(diabetic nephropathy is one of diabetes most common complication DN) to diabetic nephropathy, is more common in the diabetics of the course of disease more than 10 years, and 1 type or the type 2 diabetes mellitus patient of about 25%-40% can develop into DN.The DN early lesion is a characteristic with the hypertrophy that GBM constantly thickens with mesentery substrate, late period occurs nodular glomerulosclerosis.Clinical symptoms is albuminuria, gradual renal function injury, hypertension, edema, late period occurs the severe renal MSOF, is one of major causes of death of diabetics.In developing country, DN is one of common cause that causes renal failure in whole latter stage, and it is to be developed by DN that 35%～40% renal failure in whole latter stage is arranged approximately.
Research shows; The polyhydric alcohol metabolic pathway activation that long-term hyperglycemia causes, protein non-enzyme glycosylation, APC Protein kinase C overactivity, oxidative stress etc. have promoted the pathology process of DN from different links, and cytokine-expressing is unbalance, GLUT activates, RAS (RAS) and the renal blood flow kinetics that causes thus change and in the course of disease, also plays important effect.
The medicine of traditional blood sugar control, blood pressure, blood fat has certain meaning to the control of diabetic nephropathy.In recent years; Chinese medicine in the generation of control DN, develop and delay and obtained bigger progress aspect the carrying out property deterioration of renal function; Not only further perfect Chinese medical theory has also entered into cellular and molecular level, makes Chinese medicine in control DN, bring into play powerful effect.Although the hypoglycemic effect of Chinese medicine is not as good as Western medicine; But because Chinese medicine is many target spots, too many levels synergism; And be each item function of improving body on the whole; Therefore have clear superiority comparing with Western medicine aspect treatment of chronic diseases such as the diabetic nephropathy, more helpful to the disease process that improves and alleviate diabetic nephropathy.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine composition of treating diabetic nephropathy safely and effectively.
Another object of the present invention provides the method for preparing of this Chinese medicine composition.
Chinese medicine composition provided by the present invention is to be prepared from through extraction following parts by weight of Chinese traditional medicine: Radix Astragali 150-400 part, Radix Puerariae 150-400 part, Fructus Ligustri Lucidi 100-300 part, Radix Salviae Miltiorrhizae 100-300 part, Ramulus Euonymi 100-300 part, Rhizoma Coptidis 50-250 part.
Be preferably: Radix Astragali 200-300 part, Radix Puerariae 200-300 part, Fructus Ligustri Lucidi 150-250 part, Radix Salviae Miltiorrhizae 150-250 part, Ramulus Euonymi 150-250 part, Rhizoma Coptidis 100-200 part.
Further be preferably: 250 parts of the Radixs Astragali, 250 parts of Radix Puerariaes, 200 parts of Fructus Ligustri Lucidi, 200 parts of Radix Salviae Miltiorrhizaes, 200 parts of Ramulus Euonymis, 150 parts of Rhizoma Coptidis.
The method for preparing of Chinese medicine composition of the present invention may further comprise the steps:
1) Radix Astragali, Radix Puerariae, Ramulus Euonymi and Rhizoma Coptidis are mixed, add concentration and be ethanol water reflux, extract, 2-3 time of 40%-95%, collect extracting solution, filter, merging filtrate, relative density is the extractum of 1.20-1.35 when being concentrated into 70 ℃, drying gets extract I;
2) Fructus Ligustri Lucidi and Radix Salviae Miltiorrhizae are mixed, the ethanol water reflux, extract, of adding 5%-95% 1-3 time is collected extracting solution, filter, and merging filtrate, relative density is the extractum of 1.15-1.30 when being concentrated into 60 ℃, drying gets extract II;
3) extract I and extract II are merged, pulverize, promptly get Chinese medicine composition.
Above-mentioned steps 1) concentration described in is that the consumption of the ethanol water of 40%-95% is 5-12 a times of medical material weight, and each time of extracting is 1-3 hour;
Step 2) concentration described in is that the consumption of the ethanol water of 5%-95% is 4-10 a times of medical material weight, and each time of extracting is 1-3 hour.
In the above-mentioned preparation process medical material is extracted in two batches; Be because the main component of Radix Salviae Miltiorrhizae and Fructus Ligustri Lucidi is respectively salvianolic acid and oleanolic acid; Be acidic materials; In leaching process, may generate molecular complex with the alkaloid in the Rhizoma Coptidis or form precipitate, thereby cause extracts active ingredients to reduce.
Chinese medicine composition of the present invention is characterized in that, said composition can add on the pharmaceutics acceptable auxiliary and process various peroral dosage forms, like granule, tablet, capsule, pill etc.
Application provided by the present invention is said Chinese medicine composition is used for treating medicine for treating diabetic nephropathy in preparation application.
Chinese medicine composition of the present invention is to be prepared from through extraction in the Radix Astragali, Radix Puerariae, Fructus Ligustri Lucidi, Radix Salviae Miltiorrhizae, sharp this Six-element Chinese medicine of Rhizoma Coptidis of Ramulus Euonymi; Although the flavor number of Chinese medicine is few; But pharmacology and molecular cytobiology research show that all each single medicinal material all has the sharp therapeutical effect of stronger prevention to diabetic nephropathy; And the combination of these medicines meets Chinese medical theory, is based on motherland's medical science to pathogenetic understanding of diabetic nephropathy and guideline, confirms to come through careful screening, careful prescription, has characteristics such as prescription is rigorous, drug effect is remarkable, safe and reliable.
Diabetic nephropathy belongs to categories such as the traditional Chinese medical science " diabetes involving the kidney ", " quenching one's thirst " concurrent " edema ", " turbid urine ", " asthenia ".Its pathological changes is at kidney, and is in close relations with lung, spleen, liver, two Jiao, bladder.Characteristic of disease is a deficiency in origin and excess in superficiality, and deficiency in origin is suffered from a deficiency of the kidney for the liver spleen, and mark is real to be the stagnation of QI, blood stasis, scorching.Ancient Chinese medicine is paid attention to spleen invigorating, the kidney invigorating, diuretic during diabetic nephropathy in treatment, and along with the deepening continuously of contemporary pharmaceutical research, and modern Chinese medicine stresses also that on this basis supplementing QI and nourishing YIN, blood stasis dispellingization are turbid.
Chinese medicine composition of the present invention, from prescription, Radix Astragali invigorating QI to consolidate the body surface resistance, diuretic detumescent in the side are monarch drug; Radix Puerariae promotes the production of body fluid, quenches the thirst, and the Fructus Ligustri Lucidi replenishing kidney-YIN is ministerial drug altogether; Radix Salviae Miltiorrhizae, Ramulus Euonymi, Rhizoma Coptidis have the effect of blood circulation promoting and blood stasis dispelling and heat clearing away respectively, are adjuvant drug.Therefore full side has the effect of supplementing QI and nourishing YIN, clearing away heat and promoting production of body fluid, promoting blood circulation to remove obstruction in the collateral.
Pathogenesis from DN; Blood glucose increases, the polyhydric alcohol metabolic pathway activates, nonenzymatic glycosylation is the main reason that causes DN to produce; Therefore, the Chinese medicine that have blood sugar lowering, suppresses aldose reductase and nonenzymatic glycosylation effect can effectively stop the morbidity process of DN.Six-element Chinese medicine in the present invention's prescription all can act on each key link of DN morbidity, thereby performance fundamentally prevents and treats the effect of DN.The main component of the Radix Astragali is Radix Astragali saponin, astragalus polysaccharides, amino acids and flavonoid in the side; Radix Astragali saponin has stronger inhibitory action to aldose reductase; Can stop the conversion of glucose in the polyhydric alcohol metabolic pathway is sorbitol, thereby alleviates its infringement to kidney; In addition, Radix Astragali saponin can suppress macromolecular nonenzymatic glycosylation such as body internal protein, lipid and nucleic acid; And astragalus polysaccharides also has certain regulating action to blood glucose, and the blood glucose of laboratory animal is obviously reduced.The main component of Radix Puerariae is a puerarin, and research shows that puerarin can not only directly bring into play blood sugar reducing function, can also suppress glycosylation dead end product and its receptors bind, thereby blocks a plurality of signal paths that cause diabetic complication; In addition, puerarin also has very strong inhibitory action to aldose reductase.The main component of Fructus Ligustri Lucidi is an oleanolic acid, and oleanolic acid is a glycogen phosphorylase inhibitors, can suppress hepatic glycogen and decompose, thus blood sugar lowering.The active component of Radix Salviae Miltiorrhizae comprises fat-soluble Diterpenes composition such as TANSHINONES and water miscible salvianolic acid composition, and the both has stronger antioxidation and the effect of removing free radical, and in addition, salvianolic acid can also effectively suppress the formation of glycosylation dead end product.The main component of Ramulus Euonymi is a Quercetin, for what generally acknowledge at present aldose reductase is had stronger inhibiting flavone compound, and Quercetin can also effectively suppress nonenzymatic glycosylation, suppresses the oxidative stress status of diabetics, blood sugar lowering.Berberine in the Rhizoma Coptidis, promptly berberine also has the effect that suppresses aldose reductase and nonenzymatic glycosylation simultaneously.This shows that what contain in the Chinese medicine composition of the present invention is a large amount of to the medicative active component of DN, is that its performance is alleviated and material base of treatment diabetic nephropathy effect.
Through following experimental example curative effect of the present invention and safety are done further elaboration.
The therapeutical effect of diabetic nephropathy rat due to experimental example 1 Chinese medicine composition of the present invention is injected high fat high-carbohydrate diet associating streptozotocin
1. material
1.1 laboratory animal
70 of cleaning level SD rats, male, body weight 160 ± 20g is provided by Suzhou Industrial Park Ai Ermaite Science and Technology Ltd., the quality certification number: SCXK (Soviet Union) 2009-0001.
1.2 medicine
The enalapril maleate sheet, specification: 10mg, MSD Corp..
The preparation of Chinese medicine composition of the present invention: take by weighing Radix Astragali 300g, Radix Puerariae 300g, Fructus Ligustri Lucidi 250g, Radix Salviae Miltiorrhizae 250g, Ramulus Euonymi 250g, Rhizoma Coptidis 200g.The Radix Astragali, Radix Puerariae, Ramulus Euonymi and Rhizoma Coptidis are mixed, and the concentration that adds 9 times of amounts is 50% ethanol water reflux, extract, 2 times, each 1.5 hours, collect extracting solution, filter, merging filtrate concentrates, drying, extract I; Then Fructus Ligustri Lucidi and Radix Salviae Miltiorrhizae are mixed, the concentration that adds 8 times of amounts is 65% ethanol water reflux, extract, 3 times, each 1 hour, collect extracting solution, filter, merging filtrate concentrates, drying, extract II.At last extract I and extract II are merged, pulverize, get Chinese medicine composition.Face with preceding and be configured to required respective concentration with carboxymethylcellulose sodium solution (0.5% CMC-Na solution).
1.3 main agents and instrument
Streptozotocin (STZ), U.S. Sigma company;
Blood glucose meter and blood sugar test paper, Johnson & Johnson (China) medical apparatus and instruments company limited;
Urine protein quantitation testing cassete, Nanjing build up the biological engineering company limited;
Superoxide dismutase (SOD) test kit, the biological engineering company limited is built up in Nanjing;
Glutathion peroxidase (GSH-PX) test kit, the biological engineering company limited is built up in Nanjing;
Sodium carboxymethyl cellulose (CMC-Na), Chemical Reagent Co., Ltd., Sinopharm Group;
Step auspicious BS-300 automatic clinical chemistry analyzer, Mai Rui company.
2. method
2.1 the foundation of model
After the rat adaptability fed for 1 week, get 10 at random as the normal control group, all the other 60 is model group.Experimental session, normal rats adopt normal diet to feed, and the model group rat gives high-sugar-fat-diet (being made up of 68% normal feedstuff, 12% Adeps Sus domestica, 16% sucrose, 2.5% cholesterol and 1.5% cholate) and feeds.
Model group rat high-sugar-fat-diet is fed after 2 months the 1st lumbar injection STZ (be made into 1% STZ solution with the 0.1mmol/L citric acid solution of pH 4.4, join existing usefulness at present), and dosage is 35mg/kg; The 1st time lumbar injection carries out the 2nd injection after 2 weeks, and dosage is 40mg/kg.After the tail vein blood measuring blood, blood glucose >=16.7mmol/L shows the modeling success in the 2nd 2 week of lumbar injection.
2.2 divide into groups and administration
40 rats of modeling success are divided into 4 groups at random, 10 every group, are respectively: model group, positive controls (enalapril maleate, 1.0mg/kg), Chinese medicine composition low dose group (0.6g/kg), Chinese medicine composition high dose group (1.2g/kg).Wherein, the administration group adopts gastric infusion, and every day 1 time, the administration capacity is 0.8ml/100g; Every big 1 the filling stomach of normal group and model group rat gives isopyknic normal saline.12 weeks of successive administration.
2.3 overview
During the administration, examine the chroma of hair of respectively organizing rat, the mental status, death condition, situations such as diet and drainage 1 time weekly.
2.4 collection of specimens and biochemical indicator detect
After 12 weeks of administration finished, water was can't help in the rat fasting, adopted metabolic cage to collect the 24h urine, and the urine of collecting is stored in-20 ℃ of refrigerators, detected urine protein content.With each group rat eye socket rear vein beard blood sampling, centrifugal then, get serum, adopt automatic clinical chemistry analyzer to detect the content of its blood glucose (Glu), serum total cholesterol (TC), serum creatinine (Scr) and blood urea nitrogen (BUN).
2.5 the active mensuration of nephridial tissue SOD and GSH-PX
Each group rat is put to death, take out left kidney, remove peplos, get a fritter nephridial tissue, clean with ice-cold normal saline rinsing, filter paper is wiped away dried, weighs; On ice bath, shred, add the normal saline of pre-cooling in 1: 9 ratio with eye scissors, with glass homogenizer 0～4 ℃ of following homogenate; Low-temperature centrifugation (3000r/min; 15min), get supernatant, according to the activity of SOD and GSH-PX in the method mensuration nephridial tissue of test kit description.
2.6 renal tissue pathological examination
After rat is put to death, take out right kidney, cut open, get the part renal tissue with the fixing 12h of 10% neutral formalin along median line, dehydration, the routine paraffin wax embedded section, HE dyeing, optical microscope is observed the variation of nephridial tissue pathology down and BIAO and BEN is carried out sxemiquantitative mark.Standards of grading are: 0 is divided into no tubule damage; 0.5 be divided into damage＜5%; 1.0 be divided into damage 5%～20%; 1.5 be divided into damage 21%～35%; 2.0 be divided into damage 36%～50%; 2.5 be divided into damage 51%～65%; 3.0 be divided into damage＞65%.
2.7 statistical procedures
Experimental data is represented with
; Adopt one factor analysis of variance to carry out date processing, relatively adopt the t check between group.
3. result
3.1 ordinary circumstance
During the administration, the rats in normal control group mental status is good, and body weight gain is very fast, is quick on the draw hair color gloss, and all survivals.The model group rat is lethargy then, becomes thin, and loose and watery stool is half congealed, and hair is perpendicular matt, and tangible polydipsia, polyphagia, polyuria phenomenon occur, and wherein polydipsia and polyuria phenomenon are very obvious, during rats death is arranged.Each administration group has also occurred and the similar situation of model group, but degree all wants light than model group, and rats death is arranged.Death condition is the 4th week of administration, 1 of model group rats death; The 6th week of administration, each dead 2 of Chinese medicine composition low dose group and model group.
3.2 Chinese medicine composition is to the influence of hematuria biochemical indicator
The result is as shown in table 1, compares with the normal control group, and the content of model group rat 24h urinaryalbumin obviously increases (P＜0.01), and Glu value and TC, Scr, BUN content all obviously increase (P＜0.05, P＜0.01); Compare with model group, positive controls and Chinese medicine composition high and low dose group can obviously reduce 24h urinaryalbumin content (P＜0.05, P＜0.01), and Glu value and TC, Scr, BUN content also significantly reduce (P＜0.05, P＜0.01).
Table 1 is respectively organized the variation
of rat hematuria biochemical indicator
Compare with the normal control group,
#P＜0.05,
##P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01.
3.3 Chinese medicine composition is to nephridial tissue SOD and the active influence of GSH-PX
Compare active significantly reduce (P＜0.01) of SOD and GSH-PX in the model group nephridial tissue with the normal control group; Compare active significantly raise (P＜0.05, P＜0.01) of the SOD of positive controls and Chinese medicine composition high and low dose group and GSH-PX with model group.Each organizes kidney of rats tissue SOD and the GSH-PX activity change is seen table 2.
Table 2 is respectively organized kidney of rats tissue SOD and the active variation of GSH-PX
Compare with the normal control group,
#P＜0.05,
##P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01.
3.4 the renal tissue pathology change
The result of histopathologic examination shows, rats in normal control group glomerule clear in structure, and the renal cells marshalling, structure is normal, and no inflammatory cell infiltration is not seen mesentery substrate hypertrophy.Model group kidney of rats cortex and medullary substance boundary are fuzzy, and the glomerule dispersivity increases, proliferation of mesangial cells, the obvious swelling of podocyte; The renal tubules atrophy, the matter territorial matrix increases between renal tubules, visible massive inflammatory cells infiltrated in the matter.Compare with model group, the above-mentioned pathological change of positive controls and traditional Chinese medicine composition for treating group obviously alleviates.
The result is as shown in table 3 for the nephridial tissue histological scores, compares obviously rising (P＜0.01) of matter damage scoring between model group kidney of rats tubule and tubule with the normal control group; Compare with model group, positive controls and Chinese medicine composition all can obviously reduce damage scoring (P＜0.05, P＜0.01).
Table 3 is respectively organized kidney of rats histopathology appraisal result
Compare with the normal control group,
#P＜0.05,
##P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01.
4. conclusion
Above-mentioned experimental result shows; Chinese medicine composition of the present invention can significantly improve the renal function of DN rat due to the injection of high fat high-carbohydrate diet associating streptozotocin, and can reduce albuminuria, improves kidney antioxidant system function; Delay the course of disease of DN, thereby performance is to the preventive and therapeutic effect of DN.
Experimental example 2 Chinese medicine compositions of the present invention are to the acute toxicity test of mice
1. material
1.1 laboratory animal
A cleaning level ICR mice, male and female half and half, body weight 18～22g is provided by Yangzhou University comparative medicine center, the quality certification number: SCXK (Soviet Union) 2007-0001.
1.2 receive the reagent thing
The preparation of Chinese medicine composition of the present invention: take by weighing Radix Astragali 350g, Radix Puerariae 350g, Fructus Ligustri Lucidi 250g, Radix Salviae Miltiorrhizae 250g, Ramulus Euonymi 250g, Rhizoma Coptidis 200g.The Radix Astragali, Radix Puerariae, Ramulus Euonymi and Rhizoma Coptidis are mixed, and the concentration that adds 10 times of amounts is 50% ethanol water reflux, extract, 2 times, each 2 hours, collect extracting solution, filter, merging filtrate concentrates, drying, extract I; Then Fructus Ligustri Lucidi and Radix Salviae Miltiorrhizae are mixed, the concentration that adds 8 times of amounts is 65% ethanol water reflux, extract, 3 times, each 1.5 hours, collect extracting solution, filter, merging filtrate concentrates, drying, extract II.At last extract I and extract II are merged, pulverize, get Chinese medicine composition.Face with preceding and be configured to required respective concentration with carboxymethylcellulose sodium solution (0.5% CMC-Na solution).
2. method
Because the toxicity of this Chinese medicine composition is less, difficulty is measured LD
50So the maximum dosage-feeding experiment is adopted in this experiment, when the setting dosage was 50g/kg, this dosage was pressed system number conversion back 55 times for adult's bio-occlusion pharmaceutical quantities (medicine 0.1g/kg every day).Mice gastric infusion in the experiment, capacity are 0.4ml/10g, activity of close observation mice and death condition in 4 hours behind the disposable gastric infusion; After this respectively observe in every morning, afternoon 1 time, observed continuously 7 days.
3. result
None death in 4 hours after 30 mice administrations, most of mice is movable normal, and wherein only having 4, the mental status to occur not good, the movable minimizing, and recover normal after 1 day.In subsequently 7 days dead mouse does not appear yet, mice hair color gloss, movable, diet and drain equal no abnormality seen.After observing expiration, all mices are put to death dissection, perusal has not found that internal organs are unusual.
4. conclusion
Above-mentioned acute toxicity test shows that Chinese medicine composition oral administration safety of the present invention is better.
The specific embodiment
Through following examples the method for preparing of Chinese medicine composition of the present invention is done further explanation.
Embodiment 1
Radix Astragali 250g, Radix Puerariae 250g, Ramulus Euonymi 200g, Rhizoma Coptidis 150g are mixed, and the concentration that adds 6 times of amounts is 60% ethanol water reflux, extract, 2 times, each 1 hour, collect extracting solution, filter, merging filtrate concentrates, drying, extract I;
Fructus Ligustri Lucidi 200g, Radix Salviae Miltiorrhizae 200g mix, and the concentration that adds 9 times of amounts is 30% ethanol water reflux, extract, 2 times, each 2 hours, collect extracting solution, filter, merging filtrate concentrates, drying, extract II;
Said extracted thing I and extract II are merged, pulverize, sieve, add the mannitol of fitting; Mixing, 5% polyvidone alcoholic solution system soft material, 14 mesh sieves are granulated, 40 ℃ of dryings 4 hours; Dried granule is crossed 14 mesh sieve granulate, promptly makes granule, oral each 6g, every day 2 times.
Embodiment 2
Radix Astragali 300g, Radix Puerariae 300g, Ramulus Euonymi 250g, Rhizoma Coptidis 200g are mixed, and the concentration that adds 9 times of amounts is 50% ethanol water reflux, extract, 2 times, each 1.5 hours, collect extracting solution, filter, merging filtrate concentrates, drying, extract I;
Fructus Ligustri Lucidi 250g, Radix Salviae Miltiorrhizae 250g mix, and the concentration that adds 8 times of amounts is 80% ethanol water reflux, extract, 3 times, each 1 hour, collect extracting solution, filter, merging filtrate concentrates, drying, extract II;
Said extracted thing I and extract II are merged, and abundant dry granulation behind the mixing, granule add an amount of 0.4% magnesium stearate, mix homogeneously, and tabletting, the bag film-coat promptly makes tablet, and oral each 5, every day 3 times.
Embodiment 3
Radix Astragali 240g, Radix Puerariae 250g, Ramulus Euonymi 200g, Rhizoma Coptidis 240g are mixed, and the concentration that adds 10 times of amounts is 90% ethanol water reflux, extract, 2 times, each 1 hour, collect extracting solution, filter, merging filtrate concentrates, drying, extract I;
Fructus Ligustri Lucidi 220g, Radix Salviae Miltiorrhizae 200g mix, and the concentration that adds 5 times of amounts is 10% ethanol water reflux, extract, 2 times, each 2 hours, collect extracting solution, filter, merging filtrate concentrates, drying, extract II;
Said extracted thing I and extract II are merged, pulverize, sieve, mixing in the capsulae vacuus of packing into, promptly makes capsule, and oral each 6, every day 3 times.
Embodiment 4
Radix Astragali 350g, Radix Puerariae 250g, Ramulus Euonymi 300g, Rhizoma Coptidis 100g are mixed, and the concentration that adds 11 times of amounts is 80% ethanol water reflux, extract, 3 times, each 1 hour, collect extracting solution, filter, merging filtrate concentrates, drying, extract I;
Fructus Ligustri Lucidi 180g, Radix Salviae Miltiorrhizae 150g mix, and the concentration that adds 5 times of amounts is 95% ethanol water reflux, extract, 2 times, each 1.5 hours, collect extracting solution, filter, merging filtrate concentrates, drying, extract II;
Said extracted thing I and extract II are merged, pulverize, sieve, add an amount of adjuvant and make pill, oral each 50 balls, every day 2 times.
Embodiment 5
Radix Astragali 400g, Radix Puerariae 180g, Fructus Ligustri Lucidi 250g, Radix Salviae Miltiorrhizae 200g, Ramulus Euonymi 220g, Rhizoma Coptidis 70g press common process, and acceptable auxiliary is processed granule on the adding pharmaceutics.
Embodiment 6
Radix Astragali 200g, Radix Puerariae 200g, Fructus Ligustri Lucidi 300g, Radix Salviae Miltiorrhizae 240g, Ramulus Euonymi 200g, Rhizoma Coptidis 230g press common process, and acceptable auxiliary is processed tablet on the adding pharmaceutics.
Embodiment 7
Radix Astragali 180g, Radix Puerariae 350g, Fructus Ligustri Lucidi 140g, Radix Salviae Miltiorrhizae 280g, Ramulus Euonymi 100g, Rhizoma Coptidis 150g press common process, and acceptable auxiliary is processed capsule on the adding pharmaceutics.
Claims (7)
1. a Chinese medicine composition of treating diabetic nephropathy is to be prepared from through extraction following parts by weight of Chinese traditional medicine: Radix Astragali 150-400 part, Radix Puerariae 150-400 part, Fructus Ligustri Lucidi 100-300 part, Radix Salviae Miltiorrhizae 100-300 part, Ramulus Euonymi 100-300 part, Rhizoma Coptidis 50-250 part.
2. Chinese medicine composition as claimed in claim 1; It is characterized in that it is to be prepared from through extraction following parts by weight of Chinese traditional medicine: Radix Astragali 200-300 part, Radix Puerariae 200-300 part, Fructus Ligustri Lucidi 150-250 part, Radix Salviae Miltiorrhizae 150-250 part, Ramulus Euonymi 150-250 part, Rhizoma Coptidis 100-200 part.
3. Chinese medicine composition as claimed in claim 2 is characterized in that, it is to be prepared from through extraction following parts by weight of Chinese traditional medicine: 250 parts of the Radixs Astragali, 250 parts of Radix Puerariaes, 200 parts of Fructus Ligustri Lucidi, 200 parts of Radix Salviae Miltiorrhizaes, 200 parts of Ramulus Euonymis, 150 parts of Rhizoma Coptidis.
4. like the method for preparing of the described Chinese medicine composition of claim 1-3, it is characterized in that this method for preparing may further comprise the steps:
1) Radix Astragali, Radix Puerariae, Ramulus Euonymi and Rhizoma Coptidis are mixed, add concentration and be ethanol water reflux, extract, 2-3 time of 40%-95%, collect extracting solution, filter, merging filtrate, relative density is the extractum of 1.20-1.35 when being concentrated into 70 ℃, drying gets extract I;
2) Fructus Ligustri Lucidi and Radix Salviae Miltiorrhizae are mixed, the ethanol water reflux, extract, of adding 5%-95% 1-3 time is collected extracting solution, filter, and merging filtrate, relative density is the extractum of 1.15-1.30 when being concentrated into 60 ℃, drying gets extract II;
3) extract I and extract II are merged, pulverize, promptly get Chinese medicine composition.
5. the method for preparing of Chinese medicine composition as claimed in claim 4 is characterized in that, the concentration described in the step 1) is that the consumption of the ethanol water of 40%-95% is 5-12 a times of medical material weight, and each time of extracting is 1-3 hour;
Step 2) concentration described in is that the consumption of the ethanol water of 5%-95% is 4-10 a times of medical material weight, and each time of extracting is 1-3 hour.
6. Chinese medicine composition as claimed in claim 4 is characterized in that, said composition can add on the pharmaceutics acceptable auxiliary and process various peroral dosage forms, like granule, tablet, capsule, pill etc.
7. be used for treating the application of medicine for treating diabetic nephropathy in preparation like the described Chinese medicine composition of claim 1-3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101204469A CN102614267A (en) | 2012-04-24 | 2012-04-24 | Chinese medicinal composition for treating diabetic nephropathy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101204469A CN102614267A (en) | 2012-04-24 | 2012-04-24 | Chinese medicinal composition for treating diabetic nephropathy and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102614267A true CN102614267A (en) | 2012-08-01 |
Family
ID=46554715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101204469A Pending CN102614267A (en) | 2012-04-24 | 2012-04-24 | Chinese medicinal composition for treating diabetic nephropathy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102614267A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103272105A (en) * | 2013-06-13 | 2013-09-04 | 庞国明 | Tablet for treating diabetic nephropathy |
| CN103877374A (en) * | 2014-02-28 | 2014-06-25 | 庄妍 | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof |
| CN103877293A (en) * | 2014-04-11 | 2014-06-25 | 施维华 | Chinese medicinal preparation for decreasing blood sugar |
| CN109464505A (en) * | 2018-12-09 | 2019-03-15 | 林嗣松 | It is a kind of for treating the Chinese medicine composition of diabetes |
| CN110448562A (en) * | 2019-09-03 | 2019-11-15 | 贵州中医药大学 | Application of the lupenone in preparation treatment renal damage drug |
| CN114081910A (en) * | 2020-08-25 | 2022-02-25 | 上海市第七人民医院 | Composition for treating diabetic nephropathy, preparation method and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001022981A1 (en) * | 1999-09-29 | 2001-04-05 | Shiva Biomedical, Llc | Treatment of diabetic nephropathy and microalbuminuria |
| CN1424100A (en) * | 2002-12-30 | 2003-06-18 | 于水 | Medicines for treating and preventing diabetes and nephrodystrophy |
| CN1726967A (en) * | 2005-07-26 | 2006-02-01 | 浙江省中药研究所 | Chinese materia medica preparation for treating diabetic nephropathy, and preparation method |
| CN101584757A (en) * | 2008-05-23 | 2009-11-25 | 王伟 | A kind of Chinese medicine pharmaceutical composition that is used for the treatment of diabetic nephropathy |
-
2012
- 2012-04-24 CN CN2012101204469A patent/CN102614267A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001022981A1 (en) * | 1999-09-29 | 2001-04-05 | Shiva Biomedical, Llc | Treatment of diabetic nephropathy and microalbuminuria |
| CN1424100A (en) * | 2002-12-30 | 2003-06-18 | 于水 | Medicines for treating and preventing diabetes and nephrodystrophy |
| CN1726967A (en) * | 2005-07-26 | 2006-02-01 | 浙江省中药研究所 | Chinese materia medica preparation for treating diabetic nephropathy, and preparation method |
| CN101584757A (en) * | 2008-05-23 | 2009-11-25 | 王伟 | A kind of Chinese medicine pharmaceutical composition that is used for the treatment of diabetic nephropathy |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103272105A (en) * | 2013-06-13 | 2013-09-04 | 庞国明 | Tablet for treating diabetic nephropathy |
| CN103272105B (en) * | 2013-06-13 | 2014-11-05 | 庞国明 | Tablet for treating diabetic nephropathy |
| CN103877374A (en) * | 2014-02-28 | 2014-06-25 | 庄妍 | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof |
| CN103877293A (en) * | 2014-04-11 | 2014-06-25 | 施维华 | Chinese medicinal preparation for decreasing blood sugar |
| CN109464505A (en) * | 2018-12-09 | 2019-03-15 | 林嗣松 | It is a kind of for treating the Chinese medicine composition of diabetes |
| CN109464505B (en) * | 2018-12-09 | 2023-08-18 | 林嗣松 | Traditional Chinese medicine composition for treating diabetes |
| CN110448562A (en) * | 2019-09-03 | 2019-11-15 | 贵州中医药大学 | Application of the lupenone in preparation treatment renal damage drug |
| CN114081910A (en) * | 2020-08-25 | 2022-02-25 | 上海市第七人民医院 | Composition for treating diabetic nephropathy, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101313942B (en) | Chinese medicine composition for treating nephropathy | |
| CN102614267A (en) | Chinese medicinal composition for treating diabetic nephropathy and preparation method thereof | |
| CN101264217A (en) | Chinese medicine assembly for nourishing yin and tonifying kidney, promoting qi and promoting blood circulation, and relaxing tendons and collaterals | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| CN101264215A (en) | Medicinal composition for treating acute and chronic urarthritis and preparation thereof | |
| CN101167863B (en) | Proprietary Chinese medicine for treating diabetes and nephrosis and preparing method thereof | |
| CN101703617B (en) | Medicinal composition for treating diabetic nephropathy and preparation method thereof | |
| CN104971190A (en) | Application of dioscorea cirrhosa in preparation of medicines for preventing or treating diabetes and complications of diabetes | |
| CN117482131A (en) | Traditional Chinese medicine composition for treating chronic kidney disease and application thereof | |
| CN101336974B (en) | Blood sugar and fat reducing traditional Chinese medicine with function of comprehensively adjusting body metabolism and preparation method thereof | |
| CN103285319B (en) | Chinese medicine composition for Polycystic Ovary Syndrome in Adolescence | |
| CN101693090B (en) | Technology for preparing compound kidney inflammation tablets | |
| CN107073060B (en) | Aqueous extracts of cinnamon and astragalus | |
| CN1899415B (en) | Chinese medicine compound preparation for treating chronic hepatic disease and its preparing method | |
| CN1931233B (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
| CN103432420B (en) | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method | |
| CN101224283A (en) | Chinese traditional medicine compounds for treating diabetes and preparing method thereof | |
| CN101322767A (en) | Combination specific to valid target for treating diabetic and use thereof | |
| CN106668431B (en) | A Chinese medicinal composition with effects of warming kidney and invigorating qi, and its preparation method and application | |
| CN100536899C (en) | Chinese medicine for treating and preventing early diabetes and nephropathy | |
| CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
| CN108159282B (en) | Traditional Chinese medicine composition for treating diabetes complicated with hepatic fibrosis | |
| CN114366771B (en) | Traditional Chinese medicine composition, preparation, method and application for preventing and treating hyperuricemia | |
| CN107596065B (en) | A kind of pharmaceutical composition treated the hypertension of pregnancy and merge preeclampsia | |
| CN100525822C (en) | Capsule for treating diabetic nephropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120801 |